AbCellera Biologics (ABCL) Receivables (2020 - 2026)

AbCellera Biologics' Receivables history runs 7 years deep, the most recent figure standing at $39.2 million for Q1 2026.

• Quarterly Receivables fell 38.43% year-over-year to $39.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $39.2 million (down 38.43% YoY) and the FY2025 annual result came in at $58.3 million, up 73.41% from the prior year.
• Receivables was $39.2 million for Q1 2026 at AbCellera Biologics, down from $58.3 million in the prior quarter.
• Across five years, Receivables topped out at $334.4 million in Q1 2022 and bottomed at $20.0 million in Q1 2023.
• A 5-year average of $64.9 million and a median of $39.2 million in 2026 frame the typical range for Receivables.
• Annual changes were most pronounced in 2022 — Receivables soared 142.85% — and 2023, when it tumbled 94.02%.
• AbCellera Biologics' Receivables stood at $38.6 million in 2022, then dropped by 20.74% to $30.6 million in 2023, then rose by 9.89% to $33.6 million in 2024, then jumped by 73.41% to $58.3 million in 2025, then slumped by 32.82% to $39.2 million in 2026.
• Business Quant data shows ABCL's Receivables at $39.2 million in Q1 2026, $58.3 million in Q4 2025, and $71.2 million in Q3 2025.